Generic

Five things for pharma marketers to know: Tuesday, October 25, 2016

Five things for pharma marketers to know: Tuesday, October 25, 2016

By

Novartis' Entresto and Cosentyx miss sales forecasts; faith-based investor group urges pricing transparency; Amgen invests in digital health

Mylan's branded ad spending on the EpiPen rose 357% — to $43 million in 2015 — over five years

Mylan's branded ad spending on the EpiPen rose 357% — to $43 million in 2015 — over five years

By

In 2011 the drugmaker spent $9.4 million on branded ads for the EpiPen. By 2015, branded ad spending hit $43 million.

Five things for pharma marketers to know: Monday, August 29, 2016

Five things for pharma marketers to know: Monday, August 29, 2016

By

Mylan to launch generic EpiPen; the majority of NCCN guideline writers report conflicts of interest; Sanofi reports new trial data for Praluent

Five things for pharma marketers to know: Friday, July 15, 2016

Five things for pharma marketers to know: Friday, July 15, 2016

By

PhRMA brings on new members, Amgen partners with Daiichi Sankyo on biosimilar commercialization in Japan; Thomson Reuters to sell science unit

Five things for pharma marketers to know: Friday, April 1, 2016

Five things for pharma marketers to know: Friday, April 1, 2016

By

GSK won't patent drugs sold in low-income countries; experimental dermatitis therapy met Phase III endpoints; the FDA issues biosimilar labeling guidance

Five things for pharma marketers to know: Tuesday, October 6

Five things for pharma marketers to know: Tuesday, October 6

By

The FDA approves another generic version of Abilify; drug price increases driving profit growth; Spark plans to submit eye-drug to the FDA in 2016

Five things for pharma marketers to know: Tuesday, September 8, 2015

Five things for pharma marketers to know: Tuesday, September 8, 2015

By

Roche CEO sounds off on UK health system cost controls; Concordia Healthcare buys rare-disease drugmaker; Cipla acquires two generic drugmakers

Five things for pharma marketers to know: Thursday, July 30

Five things for pharma marketers to know: Thursday, July 30

Copaxone sales rise despite generic competition; Valeant to defend tax strategy; Bristol-Myers Squibb to test Opdivo with mogamulizumab in the US

Pfizer ends bid for OTC Lipitor

Pfizer ends bid for OTC Lipitor

By

The drugmaker told investors that the actual-use trial failed to meet the primary objectives.

Five things for pharma marketers to know: Tuesday, July 14

Five things for pharma marketers to know: Tuesday, July 14

By

The FDA approves AstraZeneca's Iressa as a first-line lung-cancer therapy; Mylan and Dr. Reddy's launch generic versions of dementia treatment Namenda; health insurer consolidation may lead to pressure on drug prices

Five things for pharma marketers to know: Monday, June 8

Five things for pharma marketers to know: Monday, June 8

By

Novartis CEO says pharma must regulate itself; Shire reportedly is in talks to buy biotech Actelion; Lilly insulin outperforms Lantus although safety concerns remain

Five things for pharma marketers to know: Thursday, May 28

Five things for pharma marketers to know: Thursday, May 28

By

The FBI is investigating Johnson & Johnson's morcellator; Sanofi purchased another priority review voucher; generic drug prices are falling at a slow rate

Five things for pharma marketers to know: Friday, May 15

Five things for pharma marketers to know: Friday, May 15

By

Genentech alums launch a new biotechnology company; Mallinckrodt sues the FDA over a drug reclassification; Sanofi takes on celiac disease

HHS says Namenda switch could cost $6 billion

The government agency said discontinuing Namenda IR before generic competition enters the market could cost Medicare and its beneficiaries billions over the next decade.

Five things for pharma marketers to know: Monday, May 11

Five things for pharma marketers to know: Monday, May 11

By

Mylan weighs Teva takeover; GSK and UNC launch research center and drug company; FDA approves Roche colorectal cancer drug diagnostic

Five things for pharma marketers to know: Thursday, May 7

Five things for pharma marketers to know: Thursday, May 7

By

A court halted the launch of Sandoz's biosimilar; GSK said it is concerned about Advair competition in the US; an FDA panel is expected to vote on a female sexual disorder drug

Pharma M&A activity reaches new heights this year

Pharma M&A activity reaches new heights this year

By

Spurred by consolidation, the life sciences industry spent more money on acquisitions in the first quarter than it did in all of 2014 combined.

Five things for pharma marketers to know: Tuesday, May 5

Five things for pharma marketers to know: Tuesday, May 5

By

Worldwide spending on cancer medications hit $100 billion last year; Bayer adds an anticoagulant to its pipeline for $100 million; GlaxoSmithKline has a new chairman

FDA takes aim at Abilify marketing material

The regulator's marketing watchdog said a sales tool makes promises that the drug's label cannot support.

FDA finalizes biosimilar guidance

The documents acknowledge biosimilars and branded biologics will differ and set assessment standards.

Five things for pharma marketers to know: Wednesday, April 29

Five things for pharma marketers to know: Wednesday, April 29

By

FDA approves generic Abilify; Mylan raises its offer to buy Perrigo; drugmakers are racing to develop drugs for celiac disease.

Five things for pharma marketers to know: Monday, April 27

Five things for pharma marketers to know: Monday, April 27

By

More pharma companies hike drug prices post-acquisition; HCV linked to increased risk of cancer; a combined Teva-Mylan would control 25% of the US generic drug market

Walgreen Co. sues Endo over pay-for-delay

Walgreen alleges Endo conspired to keep generic Opana ER off the market.

Report: US drug spending jumped 13% in 2014

Report: US drug spending jumped 13% in 2014

By

PBM Express Scripts said last year's trends reflect a major shift in how the pharmaceutical industry does business and that generics are not the bargain they once were.

Five things for pharma marketers to know: Monday, March 2

Five things for pharma marketers to know: Monday, March 2

By

Boston Scientific buys Endo men's health business; Ranbaxy generic Nexium and Valcyte approvals denied by courts; BMS receives priority review for Opdivo lung-cancer indication.

Court invalidates patent for AstraZeneca asthma drug

A New Jersey District Court ruled that the Pulmicort Respules patent is invalid, opening the door for Actavis to launch a generic version of the billion-dollar asthma drug.

Five things for pharma marketers to know: Tuesday, February 17

Five things for pharma marketers to know: Tuesday, February 17

By

Bayer exec may be Sanofi's new CEO, GSK gets a new North American Pharma lead, and Pfizer sends painkiller ALO-02 to the FDA.

Five things for pharma marketers to know: Wednesday, February 11

Five things for pharma marketers to know: Wednesday, February 11

By

BMS loses breakthrough therapy status, Gilead's pricing comes under fire in Europe, and pharma fights Italy's off-label Avastin use.

Five things for pharma marketers to know: Monday, January 26

Five things for pharma marketers to know: Monday, January 26

By

Actavis acquires Auden Mckenzie for $459 million; Sanofi/Regeneron's PCSK9 inhibitor could be first to market; Gilead strikes a deal for Harvoni and Sovaldi with four German health insurers.

Supreme Court says Teva MS patent stands (for now)

The ruling stalls generics until at least September.

OPINION

Email Newsletters